• Moonlake Immunotherapeutics posted a net loss of USD 69.71 million, widening 71.9% year over year, while operating loss deepened 47.5% to USD 70.02 million.
• Research and development expense climbed 49.5% to USD 54.52 million, while general and administrative costs increased 40.7% to USD 15.51 million.
• Cash, cash equivalents, and short-term marketable securities totaled USD 357.9 million, with cash used in operating activities rising to USD 66.29 million from the prior-year period.
• Moonlake expects to submit a BLA for sonelokimab in hidradenitis suppurativa at end of third-quarter 2026, targeting first US commercial launch in second-half 2027.
• Phase 3 program updates included 62% HiSCR75 at week 40 across VELA-1 and VELA-2, with full one-year data expected in second-quarter 2026; primary endpoint readout for IZAR-1 in psoriatic arthritis is expected in mid-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001821586-26-000007), on May 11, 2026, and is solely responsible for the information contained therein.